Page 99 - Educacional Ponenecias Congreso SEHH-STH 2020
P. 99

mal thrombopoiesis bring further evidence to the existence of a 3q21q26
syndrome. Cancer Genet Cytogenet. 1992 Apr;59(2):138-60.
4. Rogers HJ, Vardiman JW, Anastasi J, Raca G, Savage NM, Cherry AM, et al. Complex or monosomal karyotype and not blast percentage is associated with poor survival in acute myeloid leukemia and myelodysplastic syndrome patients with inv(3)(q21q26.2)/t(3;3)(q21;q26.2): a Bone Marrow Pathol-
ogy Group study. Haematologica. 2014 May;99(5):821-9.
5. Grigg AP, Gascoyne RD, Phillips GL, Horsman DE. Clinical, haematological and cytogenetic features in 24 patients with structural rearrangements of th Q
arm of chromosome 3. Br J Haematol. 1993;83(1):158-65.
6. Raya JM, Martín-Santos T, Luño E, Sanzo C, Pérez-Sirvent ML, Such E, et al.; Grupo Español de Citología Hematológica (GECH), Working Group into the Sociedad Española de Hematología y Hemoterapia (SEHH). Acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2): clinical and biologi- cal features and comparison with other acute myeloid leukemias with cyto- genetic aberrations involving long arm of chromosome 3. Hematology. 2015
Sep;20(8):435-41.
7. Sun J, Konoplev SN, Wang X, Cui W, Chen SS, Medeiros LJ, et al. De novo
acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2): a clini- copathologic and cytogenetic study of an entity recently added to the WHO classification. Mod Pathol. 2011 Mar;24(3):384-9.
8. Calderón-Cabrera C, Falantes JF, Bernal R, Pérez-Simón JA. [Myelodysplas- tic syndromes and acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3) (q21;q26.2) abnormality]. Med Clin (Barc). 2015 Sep 7;145(5):224-6.
9. Gong X,YuT,Tang Q,FuY,Wu J,ZhuY,et al.Unusual findings of acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2): a multicenter study. Int J Lab Hematol. 2019 Jun;41(3):380-6.
10. Lim G, Kim MJ, Oh SH, Cho SY, Lee HJ, Suh JT, et al. Acute myeloid leukemia associated with t(1;3)(p36;q21) and extreme thrombocytosis: a clinical study with literature review. Cancer Genet Cytogenet. 2010 Dec;203(2):187-92.
11. C h a n g V T, A v i v H , H o w a r d L M , P a d b e r g F. A c u t e m y e l o g e n o u s l e u k e m i a a s s o c i a t - ed with extreme symptomatic thrombocytosis and chromosome 3q transloca- tion: case report and review of literature. Am J Hematol. 2003 Jan;72(1):20-6.
12. Wang W, Cortes JE, Lin P, Beaty MW, Ai D, Amin HM, et al. Clinical and prognos- tic significance of 3q26.2 and other chromosome 3 abnormalities in CML in the era of tyrosine kinase inhibitors. Blood. 2015 Oct 1;126(14):1699-706.
13. Hu Z, Medeiros J, Wang W, Chen Z, Tang G, Hodjat P, et al. 3q26.2/EVI1 rearrangement is associated with poor prognosis in classical Philadel- phia chromosome-negative myeloproliferative neoplasms. Modern Pathol. 2017;30:940-5.
14. Hu Z, Hu S, Ji Ch, Tang Z, Thakral B, Loghavi S, et al. 3q26.2/EVI1 rearrange- ment in myelodysplastic/myeloproliferative neoplasms: an early event asso- ciated with a poor prognosis. Leuk Res. 2018;65:25-8.
15. Martín-Cabrera P, Jeromin S, Perglerovà K, Haferlach C, Kern W, Haferlach T. Acute myeloid leukemias with ring sideroblasts show a unique molecular signature straddling secondary acute myeloid leukemia and de novo acute myeloid leukemia. Haematologica. 2017 Apr;102(4):e125-e128.
16. Lindsley RC, Mar BG, Mazzola E, Grauman PV, Shareef S, Allen SL, et al. Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. Blood. 2015 Feb 26;125(9):1367-76.
17. Gröschel S, Sanders MA, Hoogenboezem R, Zeilemaker A, Havermans M, Erpelinck C, et al. Mutational spectrum of myeloid malignancies with inv(3)/t(3;3) reveals a predominant involvement of RAS/RTK signaling path- ways. Blood. 2015 Jan 1;125(1):133-9.
 LXII Congreso Nacional de la Sociedad Española de Hematología y Hemoterapia / Ponencias
 99













































































   97   98   99   100   101